Versatile nurse practitioner with over 20 years of hospital experience bringing demonstrated clinical expertise, proven leader skillful in uniting teams toward achieving patient-focused care goals and self-motivated. Quality-driven and efficient with strong interpersonal abilities.
-Developed clinical pathways in efforts to reduce variation in patient care, reduce delays in disposition of patient, and improve cost-effectiveness.
-Identified best practices and partnered with multidisciplinary teams including neurology, neurosurgery, internal medicine, case management and social work in efforts to meet goals established by hospital leadership including: reduced OBS length of stay, total length of stay and throughput metrics.
-Partnered with USF cardiology and interventional cardiologist on establishing Chest Pain Pathway.
-Chest Pain Pathway presented at National Observation Medicine Conference as best practice for observation medicine related to low-moderate risk chest pain complaints in emergency department.
-Responsible for staff retention, hiring, onboarding as well as provider improvement plans and termination.
-Identified need to develop split-flow process for COVID patients and main emergency department patients in efforts to keep patients and hospital staff safe.
-Partnered with large academic medical center (Rush University) to gain insight on the success of their process.
-ACS process was implemented during Delta surge June 2020
-Partnered with ED nursing leadership, ED finance team, radiology service, patient transport services and ED medical team.
-Peak capacity: >300 visits / day
-Participated on TGH COVID Taskforce Committee
-Worked across institutional silo's by repurposing TEAMHealth advance practice providers to support TGH/ USF Clinical Research.
-Provided provider support for clinical trials allowing USF to participate in unprecedented number clinical trials related to COVID-19.
-USF was recognized as one of the top performing academic centers related to COVID research nationally.
-Collaborated with USF/ TGH clinical research, TGH pharmacy, USF infectious disease, TEAMHealth emergency medicine provider team to operationalize a novel outpatient monoclonal antibody infusion clinic in 4 days- Kid Care location.
-Responsible for GEDI Infusion Clinic operations including; provider staffing, constant re-evaluation of needs assessment based on global trends, prepare for unknown and have ability to scale to meet demands.
-Provided consultation and guidance to Operation Warp Speed (private-public partnership initiated by the United States Government to facilitate and accelerate the development-manufacturing and distribution of COVID-19 therapeutics), regarding operationalizing outpatient monoclonal antibody infusion clinic as well as provided the blueprint which was used to scale government infusion clinics across America.
-Multidisciplinary manuscript published in Open Forum Infectious Disease journal- data collected in GEDI on targeted population.
-Partnered with inpatient and outpatient teams and community partners to develop robust outpatient clinical referral process to reduce COVID admissions by increasing awareness of monoclonal antibody treatment options.
-Implemented telemedicine visits to meet needs of community and patients.
*Operational development: November 23, 2020
*First Infusion: November 27, 2020 Kid Care location
*GEDI Capacity: Max capacity 90 patients per day
*Total infusions to date: >5000
-Collaborate with nursing leadership as well as frontline workers to improve throughput and facilitate flow.
-Assist with management and utilization of staffing to ensure optimal use of all resources available.
-Serve as support to all clinical staff members.
- Partner with multidisciplinary teams on efforts that focus on hospital goals as well as identifying opportunities of how to improve patient access to care while ensuring high quality of care is maintained.
-Currently-working outpatient antibiotic treatment pathway (OPAT) partnering with internal medicine / infectious disease / case management teams. Goal: reduce total length of stay without compromising quality of care.
-Partnered with infectious disease division physician leader, department of medicine chair and co-chair physician leadership on future vision of GEDI.
-Presented future vision of GEDI to interested local business partner leading to verbal commitment to financially support program leaders.
Vasey, M., Vasey, T. The modified bougie as a conduit to magnetic guided intubation optimized with industrial grade materials. Poster Presentation. European Emergency Medicine Congress (EUSEM) Poster #14795, September 9, 2018, Glasgow, Scotland. Vasey, M., Vasey T., Hoots, G. An innovative magnetic intubation technique further optimized with off label modified Sunmed Bougie and Cook Medical Bentson Guidewire. Poster Presentation. European Emergency Medicine Congress (EUSEM) Poster #18004, October 12, 2019 Prague, Czech Republic Vasey, M., Vasey, T., Jameson, A., Pupello, D. The modified bougie as conduit to magnet guided intubation optimized with industrial grade materials performed on cadaveric specimen. Oral Presentation. European Emergency Medicine Congress (EUSEM) Poster #18003, October 12, 2019, Prague, Czech Republic. 20-0151: A Randomized, Double-Blind, Placebo Controlled Trial to Evaluate the Efficacy and Safety of Nitazoxanide (NTZ) for Pre- and Post-Exposure Prophylaxis of COVID-19 and Other Viral Respiratory Illnesses (VRI) in Healthcare Workers and Others at Increased Risk of SARS-COV-2 Infection 20-0170: A Phase 1b, Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Trial of Intravenous Zotatifin in Adults With Mild or Moderate Coronavirus Disease 2019 (COVID-19) 20-0192: Furoscix Real-World Evaluation for Decreasing Hospital Admissions in Heart Failure: FREEDOM-HF Trial Protocol. 20-0260 ACTIV-4: COVID-19 Outpatient Thrombosis Prevention Trial within ACTIV-4: A multicenter adaptive randomized placebo-controlled platform trial evaluating the efficacy and safety of antithrombotic strategies in COVID-19 adults not requiring hospitalization at time of diagnosis. 20-0290 Novavax: A Phase 3, Randomized, Observer-Blinded, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine (SARS-CoV-2 rS) with Matrix-M1TM Adjuvant in Adult Participants ≥ 18 Years. 21-0037 ACTIV-6: COVID-19 Outpatient Randomized Trial to Evaluate Efficacy of Repurposed Medications. 21-0053: M20-350 Acute Hepatitis C (HCV) Infection: Safety and Efficacy of Glecaprevir (GLE)/Pibrentasvir (PIB) 8-week Treatment 21-0121: A Phase 2 Randomized, Double-blind, Placebo-controlled Trial and Open Label Extension to Evaluate the Safety and Efficacy of Deupirfenidone (LYT-100) in Post-acute COVID-19 Respiratory Disease.
ACTIVE: Florida APRN September 2013-Current
EXPIRED: Illinois RN January 2006-Expired Illinois APRN June 2012- Expired New York RN October 2010-Expired New York APRN May 2012-Expired Florida RN September 2013